疏肝解郁胶囊联合艾司西酞普兰治疗躯体疾病患者的临床研究

Clinical study of Shugan Jieyu Capsules combined with Escitalopram in treatment for patients with somatic diseases

目的探讨疏肝解郁胶囊联合艾司西酞普兰治疗躯体疾病的临床效果及安全性。方法选择2015年1月～2017年12月重庆市精神卫生中心收治的87例躯体疾病患者,按随机数字表法分为对照组和治疗组,其中对照组43例,治疗组44例。对照组予艾司西酞普兰治疗,治疗组给予疏肝解郁胶囊联合艾司西酞普兰治疗,两组均连续治疗3个月。评价并比较两组治疗前后的抑郁自评量表(SDS)、焦虑自评量表(SAS)及90项症状自评量表(SCL-90)评分。比较两组治疗过程中的治疗措施依从率、服药依从率、检查依从率及康复锻炼依从率。比较两组患者治疗过程中不良反应的发生情况。结果治疗后,两组SDS、SAS、SCL-90评分均低于本组治疗前,且治疗组SDS、SAS及SCL-90评分低于对照组(P <0.05)。治疗组的治疗措施依从率、服药依从率、检查依从率及康复锻炼依从率均明显高于对照组(P <0.05)。治疗组治疗过程中的不良反应发生率明显低于对照组(P <0.05)。结论疏肝解郁胶囊联合艾司西酞普兰能够明显改善躯体疾病患者的焦虑抑郁状态,提高治疗依从性,且安全性较好,值得在临床上推广应用。

Objective To explore clinical efficacy and safety of Shugan Jieyu Capsules combined with Escitalopram in treatment for patients with somatic diseases.Methods A total of 87 patients with somatic diseases in Chongqing Mental Health Center from January 2015 to December 2017 were selected and they were divided into control group and treatment group by the random number table method,with 43 cases in the control group and 44 cases in the treatment group.Control group was treated with Escitalopram,while the treatment group was treated with Shugan Jieyu Capsules combined with Escitalopram.The two groups were treated for 3 months continously.The self-rating depression scale(SDS),self-rating anxiety scale(SAS)scores and symptom check-list 90(SCL-90)scores of the two groups before and after treatment were evaluated and compared.The treatment compliance rate,medication adherence rate,check compliance rate,rehabilitation exercise adherence rate were compared between the two groups.Adverse reaction rate of the two groups during the treatment were compared.Results After treatment,the SDS,SAS and SCL-90 scores of the two groups were significantly lower than those before treatment,and those of the treatment group were significantly lower than the control group(P﹤0.05).Treatment compliance rate,medication adherence rate,check compliance rate and rehabilitation exercise adherence rate of the treatment group were significantly higher than the control group(P﹤0.05).The adverse reaction rate of the treatment group during treatment was significantly lower than that of the control group(P﹤0.05).Conclusion Shugan Jieyu Capsules combined with Escitalopram can improve the symptoms of anxiety and depression in patients with somatic diseases,and improve the treatment compliance,which has good security and is worthy clinical promotion.